Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials01:16

Clinical Trials

10.8K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.8K
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.0K
Statistical Software for Data Analysis and Clinical Trials01:12

Statistical Software for Data Analysis and Clinical Trials

1.6K
Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...
1.6K
Ethical Issues01:27

Ethical Issues

2.2K
Nurses are essential in patient care, upholding the ethical principles of their profession and effectively navigating ethical dilemmas. Neglecting ethical issues can lead to inadequate patient care, compromised therapeutic relationships, and moral distress among healthcare workers.
Ethical Concerns in Healthcare:
2.2K
Classifying Matter by Composition03:35

Classifying Matter by Composition

90.7K
Matter: Pure Substances and Mixtures
According to its composition, the matter can be classified into two broad categories — pure substances and mixtures. 
A pure substance is a form of matter that has a constant composition throughout with uniform properties. For example, any sample of sucrose has the same composition and same physical properties, such as melting point, color, and sweetness, regardless of the source from which it is isolated. 
A mixture is composed of two or...
90.7K
Precipitation Titration: Endpoint Detection Methods01:19

Precipitation Titration: Endpoint Detection Methods

6.0K
In argentometric precipitation titrations, endpoints can be detected visually by the Mohr, Volhard, and Fajans methods. In the Mohr method, adding a soluble chromate indicator gives an initial yellow color to the analyte solution. As the titrant is added, the first excess of silver ions forms a red silver chromate precipitate, marking the endpoint. The solution pH should be maintained at about 8 by adding solid CaCO3.
In the Volhard method, a standard excess of AgNO3 is first added to the...
6.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

On clinical trials with a high placebo response rate.

Contemporary clinical trials communications·2018
Same author

Understanding the FDA guidance on adaptive designs: historical, legal, and statistical perspectives.

Journal of biopharmaceutical statistics·2010
Same author

A method for testing a prespecified subgroup in clinical trials.

Statistics in medicine·2007
Same author

A ratio test in active control non-inferiority trials with a time-to-event endpoint.

Journal of biopharmaceutical statistics·2006
Same author

Hypotheses and type I error in active-control noninferiority trials.

Journal of biopharmaceutical statistics·2004
Same author

Evaluation of health-related quality-of-life measures in oncology drug product applications: issues and concerns.

Journal of biopharmaceutical statistics·2004

Related Experiment Video

Updated: Feb 8, 2026

Author Spotlight: Advancements in 3D Optical Imaging for Comprehensive Body Composition Assessment in Modern Research
06:48

Author Spotlight: Advancements in 3D Optical Imaging for Comprehensive Body Composition Assessment in Modern Research

Published on: June 7, 2024

2.0K

Some issues with composite endpoints in clinical trials.

George Y H Chi1

  • 1Johnson & Johnson Pharmaceutical Research and Development, L.L.C., Room 2604, 920 Route 202 S., Box 300, Raritan, NJ 08569, USA. gchi@prdus.jnj.com

Fundamental & Clinical Pharmacology
|November 30, 2005
PubMed
Summary

Composite endpoints in clinical trials pose challenges for drug efficacy. This article recommends designing trials with extended patient follow-up beyond the first event for clearer interpretation and data transparency.

More Related Videos

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K
Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

7.3K

Related Experiment Videos

Last Updated: Feb 8, 2026

Author Spotlight: Advancements in 3D Optical Imaging for Comprehensive Body Composition Assessment in Modern Research
06:48

Author Spotlight: Advancements in 3D Optical Imaging for Comprehensive Body Composition Assessment in Modern Research

Published on: June 7, 2024

2.0K
In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K
Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

7.3K

Area of Science:

  • Clinical Trials
  • Drug Efficacy
  • Biostatistics

Background:

  • Composite endpoints are frequently used as primary endpoints in clinical trials to assess drug efficacy.
  • Time-to-event composite endpoints present unique challenges in their design, analysis, and interpretation.
  • Current practices often lack sufficient patient follow-up beyond the first event, complicating data analysis.

Purpose of the Study:

  • To discuss critical issues associated with using composite endpoints as primary endpoints in drug efficacy clinical trials.
  • To highlight problems related to the validity, analysis, and interpretation of composite and component endpoints.
  • To propose solutions for improved trial design and data presentation.

Main Methods:

  • Review and discussion of existing literature and published examples of composite endpoints in clinical trials.
  • Focus on time-to-event composite endpoints and their associated challenges.
  • Development of recommendations for trial design and data reporting.

Main Results:

  • Composite endpoints, particularly time-to-event ones, can obscure the performance of individual components.
  • Lack of extended patient follow-up hinders comprehensive analysis and interpretation.
  • Published examples illustrate significant issues in validity and interpretation.

Conclusions:

  • Clinical trials using composite endpoints should prioritize patient follow-up beyond the first event.
  • Standardized formats for data presentation and analysis are proposed to enhance transparency and interpretation.
  • Careful consideration of composite endpoint design is crucial for accurate drug efficacy assessment.